AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

Mr. Pascal  Soriot D.V.M., M.B.A.

CEO & Executive Director

Dr. Aradhana  Sarin M.D.

CFO & Executive Director

Ms. Pam P. Cheng

EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board

Mr. Andrew P. Barnett

Head of Investor Relations

Mr. Jeffrey  Pott J.D.

CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board

Gonzalo  Vina

Head of Global Media Relations

Dr. Ruud  Dobber Ph.D.

Executive Vice-President of BioPharmaceuticals Business Unit

Dr. Susan Mary Galbraith M.D., Ph.D.

Executive Vice President of Oncology Research & Development

Mr. Leon  Wang

Executive VP of International & China President

Ms. Iskra  Reic

Executive Vice-President of Vaccines & Immune Therapies

AZN's next earnings is on February 6, 2025 (Before Market Open)

AZN's latest dividend is 0.776 GBP on August 8, 2024

AstraZeneca PLC (AZN) Stock Analysis, Discussion Forum and Financial Metrics - LSE Exchange

AstraZeneca PLC (AZN) Earnings Report Date and History | LSE

AZN's next earnings is on February 6, 2025 (Before Market Open)

When is the earnings report for AZN?

AZN Earnings History

AZN's latest dividend is 0.776 GBP on August 8, 2024

AZN Stock Discussion Forum and Message Board

News for LSE: AZN